Advertisement
Advertisement
U.S. markets close in 2 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Achieve Life Sciences, Inc. (ACHV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6137+0.2337 (+6.91%)
As of 01:25PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.3800
Open3.3700
Bid3.6000 x 2200
Ask3.6500 x 1800
Day's Range3.3700 - 3.7100
52 Week Range3.3700 - 9.4200
Volume28,276
Avg. Volume42,980
Market Cap34.987M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACHV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Achieve Life Sciences, Inc.
    Daily Spotlight: VIX Back to 30Fear has returned to the equity market, as inflation readings have failed to cool dramatically, the Federal Reserve remains on a long-term course toward higher rates, U.S. mid-term elections approach, Vladimir Putin threatens the use of nuclear weapons in Eastern Europe, and the global economy reels toward recession. The VIX Volatility Index is a key gauge of investor sentiment and has been elevated above 20 for most of the past two years. Last Friday, after a 486-point drop in the Dow Jones Industrial Average, the VIX closed at 29.92 after touching 32 earlier in the day. A little more than a month ago, the VIX was below 20, and seemingly headed lower as the U.S. consumer economy appeared to be in good shape. How can the market turn so quickly? Investors are always looking ahead, and the latest data (the CPI two weeks ago, the Fed's 75-basis-point hike last week) point toward near-term challenges for the economy, companies, and corporate earnings. New data will be out this week (the Fed's favorite inflation gauge, the PCE indices) and corporate earnings reports will start to flow in mid-October. We expect volatility to remain high, yet the pullback in stock prices unearths some attractive valuations. Buy low and sell high. We think investors should continue to focus on well-managed companies with clear growth objectives and clean balance sheets.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Simply Wall St.

    Health Check: How Prudently Does Achieve Life Sciences (NASDAQ:ACHV) Use Debt?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

  • Benzinga

    Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

    Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers. The 6- and 12-week cytisinicline treatments demonstrated significantly better quit rates than placebo, with odds ratios of 8.0 and 6.3, respectively. Subjects who received 12 weeks of cytisinicline treatment had a 6.3 times higher likelihood of quitting smoking during the last 4 weeks of treatment th

  • Benzinga

    Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

    Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers. ORCA-3 participants will be randomized to one of three study arms to evaluate cytisinicline administered for either 6 or 12 weeks, compared to placebo. Related: Achieve Life Sciences Secures M Loan Facility To Fund Smoking Cess

Advertisement
Advertisement